Owing to its inhibitory activity against PKCα, PKCβ, and PKCγ, as well as multiple receptor tyrosine kinases, midostaurin has demonstrated notable efficacy in clinical trials for solid tumors and acute myeloid leukemia (AML) [321, 322, 323]. Here, PRKCB is linked to acute myeloid leukemia.